Compare Novavax Inc (NVAX) vs SK Hynix (SKHY) Price & Performance

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.

SKHY trades at $185.55, up 4.83% today, with strong fundamental performance including 85.62% net income margin and consistent earnings beats. The stock shows neutral technical signals near pivot point $186, with support at $183 and resistance at $189. Recent news highlights SKHY's leadership in AI memory chips with 50% HBM market share and strong demand from AI infrastructure buildout.

Outlook remains positive with 100% analyst buy ratings and $248 consensus price target representing 34% upside. Key risks include memory cycle volatility and competitive pressures, but strong HBM positioning and expanding AI partnerships provide growth catalysts. Revenue growth accelerated to 85.61% profit margin in 2026 trends.